







Company	Platform	Doses	Non-clinical results	Number of people who got vaccine	Protection from hospitalization /death due to COVID-19	Protection from severe disease from COVID-19 (may not be hospital)	Efficacy against milder disease from COVID-19
	mRNA-1273 mRNA in lipid nanoparticle	2	Neutralizing Abs; Strong Th1 response; protection from challenge	~15,000	100%	100% (30 cases in placebo arm; 0 in vaccine)	94.1%
	BNT162b2 mRNA in lipid nanoparticle	2	Neutralizing Abs; Strong Th1 and Th2 response; protection from challenge	~18,600	100%	100% (9 cases in placebo arm; 0 in vaccine)	95%
	AZD 1222 Non-replicating Chimp Adenovirus-DNA	2	Neutralizing Abs; Strong Th1 and Th2 response; protection from challenge	~5800	100%	100% (15 in placebo; 0 in vaccine)	90% half-full-dose; 70% overall; 76% with 1 dose
	JNJ-78436725 Non-replicating human adenovirus/DNA	1	Neutralizing Abs; Strong Th1 and Th2 response; protection from challenge	~22,000	100%	85% (across South Africa, U.S., Latin America including Brazil)	72% US; 66% Latin America; 57% S. Africa (95% B1.351)
	NVX-CoV2373 Spike protein/RBD + Matrix M adjuvant	2	Neutralizing Abs; protection from challenge	~9700	100%		89.3% UK; 60% S. Africa
	Ad26 and Ad5 adenovirus/DNA	2	Neutralizing Abs; Strong Th1 and Th2	~14964	100%	100% (20 in placebo; 0 vaccine)	91.6%